Product Name: BICD2 Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, WB
Applications: BICD2 antibody can be used for detection of BICD2 by Western blot at 1 – 2 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: BICD2 antibody was raised against a 13 amino acid synthetic peptide from near the carboxy terminus of human BICD2.The immunogen is located within the last 50 amino acids of BICD2.
Host Species: Rabbit
Purification: BICD2 Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 302-22-7
Product: Chlormadinone (acetate)
Buffer: BICD2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: BICD2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: BICD2 Antibody: SMALED2, bA526D8.1, KIAA0699, Protein bicaudal D homolog 2, Bic-D 2
Accession NO.: CAI41013
Protein Ino: 57208854
Official Symbol: BICD2
Geneid: 23299
Background: BICD2 Antibody: BICD2 is the second human homolog discovered to the Drosophila Bicaudal-D protein that forms part of the cytoskeleton and mediates the correct sorting of mRNAs for oocyte- and axis-determining factors during oogenesis. Similar to the highly homologous protein BICD1, BICD2 can bind to dynein-dynactin complex, primarily through the dynamitin subunit of dynactin. The C-terminus of BICD2 targets the protein to the Golgi complex while the N-terminal domain of BICD2 co-immunoprecipitates with cytoplasmic dynein, suggesting BICD2 plays a role in the dynein-dynactin interaction on the surface of membranous organelles. Mice engineered to overexpress the BICD2 amino terminal domain in neurons developed amyotrophic lateral sclerosis (ALS)-like features such as Golgi fragmentation, neurofilament swelling in proximal axons, etc., suggesting that impaired dynein/dynactin function may explain some of the pathological features observed in ALS patients.
PubMed ID:http://aac.asm.org/content/42/2/473.abstract
